Contact us

877-469-1TRM
424-208-8866

Study to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects

A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) Plus Lenalidomide (Revlimid®) Regimen Versus an Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Older Subjects w/Newly Diagnosed Acute Myeloid Leukemia Lenalidomide (Revlimid) II Open and Accruing